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Abstract
Background: Many patients with diabetes mellitus (DM) require a combination of antidiabetic
drugs with complementary mechanisms of action to lower their hemoglobin A1c levels to achieve
therapeutic targets and reduce the risk of cardiovascular complications. Linagliptin is a novel
member of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of antidiabetic drugs. DPP-4 inhibitors
increase incretin (glucagon-like peptide-1 and gastric inhibitory polypeptide) levels, inhibit glucagon
release and, more importantly, increase insulin secretion and inhibit gastric emptying. Currently,
phase III clinical studies with linagliptin are underway to evaluate its clinical efficacy and safety.
Linagliptin is expected to be one of the most appropriate therapies for Japanese patients with DM,
as deficient insulin secretion is a greater concern than insulin resistance in this population. The
number of patients with DM in Japan is increasing and this trend is predicted to continue. Several
antidiabetic drugs are currently marketed in Japan; however there is no information describing the
effective dose of linagliptin for Japanese patients with DM.
Methods: This prospective, randomized, double-blind study will compare linagliptin with placebo
over a 12-week period. The study has also been designed to evaluate the safety and efficacy of
linagliptin by comparing it with another antidiabetic, voglibose, over a 26-week treatment period.
Four treatment groups have been established for these comparisons. A phase IIb/III combined study
design has been utilized for this purpose and the approach for calculating sample size is described.
Discussion: This is the first phase IIb/III study to examine the long-term safety and efficacy of
linagliptin in diabetes patients in the Japanese population.
Trial registration: Clinicaltrials.gov (NCT00654381).
Background
Diabetes mellitus affects around 171 million people
worldwide and this figure is expected to double by the
year 2030. Type 2 diabetes mellitus (T2DM) accounts for
between 90 and 95% of all cases of diabetes [1]. In Japan,
the Ministry of Health, Labour and Welfare estimates that
there are approximately 8.2 million people "strongly sus-
pected of having diabetes" and there are about 10.5 mil-
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lion people "for whom the possibility of diabetes cannot
be ruled out", suggesting that there could be as many as
18.7 million Japanese sufferers. In other words, one in
four adults in Japan may have or may be in the process of
developing diabetes [2]. Estimates suggest that 2.3 million
Japanese people are currently receiving medical care for
diabetes and reports place diabetes as the third most com-
mon cause of outpatient visits for Japanese men. The dis-
ease is also associated with significant co-morbidity and
mortality, and ranks as the tenth most likely cause of
death for Japanese men and the ninth for Japanese
women [2]. Type 2 diabetes mellitus is a progressive dis-
ease and, once diagnosed, the treatment pathway involves
an increasingly complex combination of treatments as the
disease worsens. Despite the various treatments available,
there is no cure and treatment regimens often become
more complex as patients demonstrate progressive deteri-
oration of glycemic control. Therefore, there is a recog-
nized clinical need for safe and effective new treatments
for T2DM. Dipeptidyl peptidase-4 (DPP-4) inhibitors are
one such class of antidiabetic agents that have recently
been introduced into the clinical armamentarium.
The purpose of a drug development program is to estab-
lish through clinical trials whether a drug displays accept-
able levels of safety and tolerability, and to establish
whether the drug's actions are both beneficial and clini-
cally relevant. In T2DM, the gold standard measure of effi-
cacy is the impact of the antidiabetic agent on levels of
glycosylated haemoglobin (HbA1c). Although no superior
marker to HbA1c has yet been proposed, its use raises a
number of methodological and ethical challenges in
terms of conducting clinical trials. In general, antidiabetic
agents effect changes in HbA1c levels by only a few percent
(typically 0.5-2%). In contrast, patients vary widely both
in their individual HbA1c levels (7-14%) and in disease
response to various treatments. The inherent variability of
HbA1c levels within the diabetic population and the rela-
tively small changes caused by treatment dictate that clin-
ical studies attempting to establish the efficacy of a new
drug for T2DM need to involve relatively large numbers of
subjects to demonstrate any statistically significant results
confirming efficacy. Where studies compare the efficacy of
one drug relative to another, the number of subjects
required needs to be greater still. Pressure to recruit suffi-
cient numbers of patients in a timely fashion makes it
impractical to conduct such studies using treatment-naïve
patients alone, where recruitment ideally should occur at,
or around the time of diagnosis. The design of studies
must therefore consider using patients already receiving
treatment for diabetes. This introduces a further compli-
cating factor, as previous exposure to an antidiabetic treat-
ment may affect patient response to new treatment.
Although HbA1c serves as an excellent indicator of change
in the general level of individual glycemic control, it takes
2 - 3 months for any treatment-related changes to be fully
represented within the HbA1c  measurement for any
patient. This influences the design and implementation of
clinical trials of T2DM in several ways. First, studies must
be conducted either in treatment-naïve patients, or in
patients who have undergone a suitable treatment wash-
out period so that HbA1c values are allowed to return to
pre-treatment levels. Withholding therapy known to ben-
efit a patient for up to 2 - 3 months could be considered
unethical. Second, in light of the turnover of red blood
cells, patients need to be exposed to an investigational
drug for up to 12 weeks to demonstrate the full effect of
the drug on HbA1c levels. Under these circumstances, if a
study employs a standard placebo-controlled design,
patients in the placebo group might go for up to 24 weeks
without receiving diabetes treatment. Thus, the challenge
in conducting clinical trials in T2DM is to design suitably
powered efficacy studies that are both practicable and eth-
ical. It is proving increasingly difficult to deliver such stud-
ies using traditional randomized, placebo-controlled
designs. The employment of more complex trial designs
that are appropriately powered may serve to address some
of these challenges.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new and
promising class of agents for the treatment of T2DM. Lin-
agliptin is a novel member of the DPP-4 inhibitor class
that may offer added clinical benefits over similar agents.
These include a long half-life consistent with once-daily
dosing, non-renal excretion that will not require dose
adjustment following loss of renal function and excellent
safety and tolerability profiles [3-6]. As DPP-4 inhibitors
increase insulin secretion, they are expected to become an
important treatment for T2DM in Japanese patients, who
tend to be leaner than patients in Western countries. Lean
patients are more likely to be older at diagnosis, possess
an immune component to their T2DM, and demonstrate
certain pathophysiological characteristics, notably less
insulin resistance and poorer insulin secretory capacity
[7]. The present study proposes to investigate the effect of
linagliptin on HbA1c levels in a Japanese population at
two different doses (5 mg and 10 mg). It is possible that
these patients will respond differently than Caucasian
patients due to genetic differences. Differences in the
pharmacokinetic and/or pharmacodynamic behaviour of
drugs between Japanese subjects and subjects from other
ethnic backgrounds have been observed, for example for
the oral contraceptive Org 30659 [8] and the anti-choles-
terol agent, rosuvastatin [9]. As a consequence, guidance
from the Pharmaceutical and Medical Devices Agency
(PMDA) in Japan recommends that the dose-responseTrials 2009, 10:82 http://www.trialsjournal.com/content/10/1/82
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relationship for any new drug is confirmed in the Japanese
population and that treatment is evaluated in 'adequate
numbers of Japanese cases' [10].
The primary objectives of the proposed study are to com-
pare the efficacy of linagliptin versus placebo in lowering
HbA1c in a 12-week study conducted in Japanese patients
with T2DM, and to examine the efficacy of linagliptin ver-
sus the antidiabetic agent voglibose. The study will also
evaluate the long-term safety profile of linagliptin for up
to 52 weeks. The study design, primary endpoints, patient
inclusion/exclusion criteria and statistical methods used
to calculate the study sample size are described.
Methods/Design
Study Setting
This is a randomized, double-blind study with both a pla-
cebo- and an active-controlled parallel group. It is con-
ducted in 47 centers in Japan. To be eligible for study
enrollment, male or female subjects are required to be
Japanese patients aged 20-80 years with T2DM (baseline
HbA1c  levels of 7.0-10.0%). Patients taking oral anti-
hyperglycemic drugs at screening are eligible to participate
if they have a mean HbA1c value of > 7 - < 9% during the
washout period. Other inclusion criteria include a stable
HbA1c value (less than 10% variation during the last 2
weeks of the 4-week washout period) and a body mass
index less than 40 kg/m2 at randomization. Patients are
excluded from the study if they violate these inclusion cri-
teria or if they meet the exclusion criteria specified in the
protocol.
All patients must give written consent to participate in the
study, which has been approved by an Institutional
Review Board at each center. This study is registered with
the US National Institutes of Health website: ClinicalTri-
als.gov (NCT00654381).
Study Stages
This study includes three different stages, each with spe-
cific objectives, and will utilize four treatment arms (A-D)
(see Figure 1). The objective of Stage 1 is to compare
changes in HbA1c levels in patients receiving linagliptin
with those receiving placebo at 12 weeks. The objective of
Stage 2 is to compare changes in HbA1c levels in patients
receiving linagliptin with those receiving voglibose after
26 weeks of treatment. The objective of Stage 3 is to deter-
mine the long-term safety and tolerability of linagliptin.
Study Design Figure 1
Study Design.
Placebo (N=63)
Linagliptin 5 mg  
(N=126)
Linagliptin10 mg 
(N=126)
Voglibose (N=126)
(14 weeks) (12 weeks)
Extension treatment phase
(26 weeks)
Comparison
vs. Placebo
Comparison
vs. Voglibose
Linagliptin 5 mg
Linagliptin 5 mg
Linagliptin 10 mg
Linagliptin 5 mg
Linagliptin 10 mg
Linagliptin 10 mg
Voglibose
Placebo
Placebo
Placebo
Placebo
Double-blind treatment phase Washout
(4 weeks)
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Initially, patients will undergo a washout period where
they receive placebo for 4 weeks after providing informed
consent. Following the washout period, eligible patients
will be randomized to one of four treatment arms (pla-
cebo [A]; linagliptin 5 mg [B]; linagliptin 10 mg [C]; or
voglibose 0.6 mg [D]). Patients randomized to Group A
will receive a placebo for 12 weeks after which they will
receive linagliptin for 40 weeks; patients in the Group B
(linagliptin 5 mg) and Group C (linagliptin 10 mg) treat-
ment arms will receive the study drug for up to 52 weeks.
Patients randomized to Group D (voglibose 0.6 mg) will
receive the treatment for 26 weeks after which they will be
switched to linagliptin for 26 weeks (Figure 1). The treat-
ment change to linagliptin in Groups A and D involves an
additional patient randomization to either 5 mg or 10 mg,
from which data on the long-term safety and tolerability
of linagliptin will be collected. The doses of linagliptin
used in this study are based on previous reports of DPP-4
activity in Japanese T2DM patients [11].
Study Endpoints
The proposed comparison of efficacy between linagliptin
(5 and 10 mg) and both placebo and voglibose is based
on changes in HbA1c levels from baseline at 12 and 26
weeks, respectively. The primary comparison between lin-
agliptin 10 mg and placebo is planned at 12 weeks, and
the comparison between linagliptin 10 mg and voglibose
0.6 mg is planned at 26 weeks. To investigate dose-
response relationships, a subsequent comparison is made
at those time points between linagliptin 5 mg and placebo
(12 weeks) and voglibose 0.6 mg (26 weeks).
Other parameters of interest measured will include inhibi-
tion of plasma DPP-4 activity, the proinsulin/insulin
ratio, the homeostasis model assessment (HOMA) indices
for insulin resistance and insulin secretion, body weight,
waist circumference and plasma concentrations of lina-
gliptin. Adverse event, safety, laboratory and hematology
data will be collected during the study and will form part
of the secondary endpoint data for determining the long-
term safety profile of linagliptin.
Patient reported outcomes will be assessed using the Dia-
betes Treatment Satisfaction Questionnaire (DTSQ) mod-
ified by Ishii [12], consisting of 6 items assessing
treatment satisfaction and 2 items assessing the perceived
frequencies of hyperglycaemia and hypoglycaemia.
Study Randomization
Four treatment arms are used to investigate the effective
dose and safety profile of linagliptin in the study popula-
tion. Randomization will be based on the Zelen rule [13]
and follow a predefined allocation ratio of 2:2:2:1 (lina-
gliptin 5 mg: linagliptin 10 mg: voglibose: placebo). Allo-
cation to treatment groups is balanced for the potentially
confounding effects of patient background and baseline
characteristics, HbA1c  (stratified into two categories; <
8.5% and ≥ 8.5%), the number of pre-study use of antid-
iabetic drugs, gender and study site.
Treatment allocation is conducted by a sponsor-inde-
pendent contractor. Following informed consent, the
investigator completes a registration form that is sent to
the allocation center. The registration form includes data
on the subjects' inclusion and exclusion criteria. After
receiving the registration form, the allocation center sends
a registration report to the investigator. The investigator
confirms that the patient satisfies the study criteria and
sends a second registration form to the allocation center
once the 4-week washout period is completed. The alloca-
tion center randomizes the patient according to the pre-
defined criteria above and this information is provided to
the investigator. Randomization is done once at the
enrollment of study. At the randomization after the
enrollment, patients are assigned, to 6 groups: placebo -
linagliptin 5 mg, placebo - linagliptin 10 mg, linagliptin 5
mg, linagliptin 10 mg, voglibose - linagliptin 5 mg, and
voglibose - linagliptin 10 mg. Therefore all patients ulti-
mately take either linagliptin 5 mg or 10 mg, unless they
withdraw or drop out the study.
Statistical analysis
The statistical analyses are performed on an intention-to-
treat basis. The full analysis dataset (FAS) is described in
the ICH E9 guidelines [14], and is defined as the proposed
analysis dataset for efficacy. The procedures followed are
described below.
Analysis for the primary endpoint
Baseline glycosylated hemoglobin levels and the number
of antidiabetic drugs used before study enrollment are
included in the model as covariates.
Changes in HbA1c level from baseline to 12 weeks of lina-
gliptin treatment are analyzed in accordance with the
model below, in order to compare with placebo in the
double-blind treatment phase:
Where:
yijk : change in HbA1c at 12 weeks from baseline
BHbA1ci : HbA1c of i-th patient at baseline (i = 1, 2,..., n)
Dosej : j-th dose group (j = 0: placebo, 1: 5 mg, 2: 10 mg)
Diabtreatk : number of previously used antidiabetic drugs
(k = 0: no treatment, 1: one antidiabetic drug, 2: two anti-
diabetic drugs)
y BHbA c Dose Diabtreat ijk i j k ijk =+ + + aa a e 12 3 1Trials 2009, 10:82 http://www.trialsjournal.com/content/10/1/82
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Comparisons conducted at 12 weeks are between linaglip-
tin and placebo. Patients who received placebo for 12
weeks and are then randomized to receive either linaglip-
tin 5 mg or 10 mg are excluded from this analysis. Values
of HbA1c following treatment with linagliptin are to be
compared with those for voglibose after 26 weeks if lina-
gliptin treatment fails to achieve a statistically significant
difference in HbA1c levels relative to placebo (primary
comparison dose at 12 weeks). The dosing schedule for
linagliptin increases from 5 mg to 10 mg during study if
linagliptin 5 mg fails to demonstrate superiority to pla-
cebo at 12 weeks. In addition, the study stops if neither of
the linagliptin arms shows statistically significant differ-
ences from placebo in HbA1c levels at 12 weeks.
The model for HbA1c at 26 weeks is:
Where:
yijk : Change in HbA1c at 26 weeks from baseline
HbA1ci : HbA1c of i-th patient at baseline (i = 1, 2,..., m)
Drugj: j-th treatment group (j = 1:5 mg, 2:10 mg, 3:voglib-
ose)
Diabtreatk : number of previously used antidiabetic drugs
(k = 0:no treatment, 1:one antidiabetic drug, 2:two antid-
iabetic drugs)
Comparisons for HbA1c between groups are performed
weekly by the closed testing procedure [15]. No formal
analysis will be performed for safety and tolerability data
collected during the three stages of the study. Data will be
summarized in terms of treatment received.
Sample size
Sample size calculations are performed using nQuery
Advisor® 6.0 (Statistical Solutions Ltd, Ireland) software
on a Windows-based personal computer. On the basis of
clinical studies conducted in Japan and other countries, it
is estimated that the overall mean change in HbA1c levels
after treatment with linagliptin 5 mg QD for 12 weeks will
be approximately 0.5% compared with 0% in placebo.
This will provide an overall mean between-groups treat-
ment difference of 0.5%. Experience also suggests that the
standard deviation of this difference will be approxi-
mately 0.9%. Employing an accepted one-sided statistical
significance threshold of 2.5% and taking into account
the weighting for placebo and linagliptin group randomi-
zation ratios (1:2), it is possible to predict a 90% power
for the study with sample sizes of no less than 52 patients
in the placebo group and no less than 104 patients in the
linagliptin groups.
Assuming that HbA1c levels for the linagliptin treatment
groups will continue to fall with ongoing therapy, esti-
mates suggest that the mean change in HbA1c levels from
baseline after a 26 week treatment with linagliptin 5 mg,
will be approximately 0.7%, compared with 0.25% for
voglibose 0.6 mg. It is expected that this difference
between treatments will be reflected in a mean difference
in HbA1c levels from baseline of 0.45% [16]. With a stand-
ard deviation of the difference at 1.0% and the level of sig-
nificance set at 2.5% (one-sided analysis), sample sizes of
105 or more in each group provide a power greater than
90%.
Experience derived from previous clinical trials in patients
with T2DM suggests that a discontinuation/dropout rate
of approximately 15% can be expected during the current
52-week trial. Assuming that the present study will experi-
ence a similar level of subject discontinuation, it is possi-
ble to adjust the recruitment targets to maintain study
power in anticipation of similar attrition levels. A target
sample size of 63 patients in the placebo group and 126
patients each in the linagliptin and voglibose treatment
groups (a total of 441 patients overall) is therefore
required to power this study appropriately to achieve its
primary objectives.
The sample size in the linagliptin group also appears to
satisfy the requirements for evaluation of safety in the
clinical development of new drugs expected for long-term
use in non-fatal diseases [17].
Discussion
The design of the present study is adopted as a means of
addressing some of the ethical and methodological chal-
lenges in studying new drugs in T2DM populations.
Glycosylated hemoglobin has emerged as the accepted
marker of glycemic control and clinical efficacy in studies
of diabetes [18]. The nature of HbA1c, particularly its 2 - 3
month period for turnover, tends to dictate the time
course of T2DM clinical trials. Similarly the inter-patient
variability in terms of the levels of HbA1c and its response
to various treatments dictate that studies must recruit rel-
atively large numbers of patients to demonstrate statisti-
cally significant changes in HbA1c compared with placebo
[19]. The challenge in recruiting sufficient numbers of
patients is still greater if a study intends to compare the
efficacy of two or more different treatments. To make
treatment studies in T2DM more practical, it is necessary
not to limit the patient population only to treatment-
naïve patients. This introduces the potentially confound-
ing factor of prior exposure to antidiabetic drugs and its
potential impact on both baseline values and treatment
response. To minimize this effect it is necessary to provide
a sufficient treatment washout period to reduce the
impact of the previous treatment. However, to allow
y BHbA c Drug Diabtreat ijk i j k ijk =+ + + bb b e 12 3 1Trials 2009, 10:82 http://www.trialsjournal.com/content/10/1/82
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HbA1c to return to baseline levels it would be necessary for
the washout period to last 2-3 months, and if the study
design involves a placebo arm, this would mean a signifi-
cant number of patients going without treatment for an
extended period.
Withholding treatment from patients for a prolonged
period might be considered unethical. Therefore, the
present study uses a 4-week washout period. Clearly, 4
weeks is insufficient for HbA1c levels to return to the base-
line level before initiation of the previous treatment.
However, by adopting this approach it is hoped that we
may address some of the concerns frequently raised about
prolonged treatment withdrawal in clinical trials [20]. The
statistical analysis plan and analysis of the power of the
study, therefore, take into account the fact that HbA1c lev-
els at treatment initiation will most likely incorporate an
aspect of the pre-study treatment response, the antidia-
betic drug used and the previous extent of disease control
per patient.
The study design was selected to reduce the number of
patients required to undergo a prolonged placebo expo-
sure by employing an imbalanced randomization (pla-
cebo:linagliptin 5 mg:linagliptin 10 mg:voglibose =
1:2:2:2). Using this biased treatment allocation approach,
it is possible to minimize the potentially unethical expo-
sure of patients to placebo while maintaining sufficient
power to complete the primary statistical comparison.
Data after 16 weeks of placebo treatment can be useful for
determining a true baseline (treatment naïvety) because
any underlying glycemic controlling effects of prior antid-
iabetic treatment should have had sufficient time to
reverse. The 16 week data for glycosylated HbA1c levels in
the placebo group will not be included in any compari-
son, but instead will be viewed as an indication of the
study population's baseline HbA1c values in the absence
of the potentially confounding residual effects of previous
therapies. A similar number of patients are needed to
demonstrate the non-inferiority or superiority of linaglip-
tin to placebo under imbalanced randomization and to
voglibose. The study design can also be sufficiently pow-
ered for detecting statistically significant differences
between linagliptin and placebo or voglibose. Using the
methods described, we have calculated that this can be
achieved without markedly increasing the number of sub-
jects needed.
The efficacy of short term linagliptin treatment in Japa-
nese T2DM patients was reported by Kanada et al [11]. We
set the one-sided hypotheses (2.5% statistically significant
level) in the present study as the efficacy of linagliptin is
expected to show significant superiority to placebo or
voglibose. The efficacy of linagliptin is established only in
the case that linagliptin shows superiority to placebo and
voglibose simultaneously. Therefore, adjustment for mul-
tiple hypotheses is not carried out.
Our study design may also facilitate recruitment relative
to other methods. In clinical studies of antidiabetic drugs
as monotherapy, all patients randomized to placebo
groups receive only placebo; therefore, there are no per-
ceived benefits for these patients. The use of placebo-only
groups in clinical studies may cause patients to hesitate
when asked to participate, as they are aware that they have
a chance of receiving inadequate treatment during the
trial. In the present study, patients receive placebo for a
maximum of 16 weeks after which they are given active
treatment. This design may serve to aid patient recruit-
ment in clinical studies. Similarly, study designs which
incorporate multiple objectives within a single study may
reduce the burden of recruitment on the development
program by maximizing the information derived from
every study. This study investigates the efficacy of two dif-
ferent doses of linagliptin versus placebo (at 12 weeks),
compares the relative efficacy of linagliptin versus voglib-
ose (at 26 weeks) and provides long-term (52 week) safety
data. Combining the objectives into a single study effec-
tively cuts the pre-study clinical workup that would be
needed if these investigations were conducted as three
separate studies, thus reducing the patient recruitment
burden. Other ongoing Phase III trials are evaluating lina-
gliptin as both monotherapy and as add-on therapy to
commonly used diabetes medications. It is anticipated
that these trials combined with the results of the present
study will support the suitability of linagliptin as a further
treatment option for type 2 diabetes patients in Japan.
In conclusion, a continuous flow study design has been
applied to investigate three distinct areas of interest
related to the novel DPP-4 inhibitor linagliptin in Japa-
nese diabetes patients. The design described offers several
logistical and ethical advantages, while remaining ade-
quately powered to generate informative results for this
patient population. Full results from this trial will be pub-
lished in 2010.
Competing interests
This trial was supported by Boehringer Ingelheim. With
the exception of MT, all of the authors are full-time
employees of Boehringer Ingelheim. Involvement in this
trial does not conflict with the professional activities of
MT.
Authors' contributions
All authors read and approved the final manuscript. YH as
an investigator in the study, drafted the manuscript and
has made a substantial contribution to acquisition of
data.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Trials 2009, 10:82 http://www.trialsjournal.com/content/10/1/82
Page 7 of 7
(page number not for citation purposes)
Acknowledgements
We wish to thank Dr. Hans-Juergen Woerle and Dr. Mathias Senger for 
supporting us. We also appreciate the support of Ms. Yumiko Sawada for 
providing us with documents for generating this paper. Medical writing and 
editorial support was provided by Patrick Foley of PHASE II International 
Ltd, with the financial support of Boehringer Ingelheim.
References
1. World Health Organization   [http://www.who.int/diabetes/facts]
2. Ministry of Health, Labour and Welfare (Japan): Diabetes Survey 2006.
3. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA: Safety,
tolerability, pharmacokinetics, and pharmacodynamics of
single oral doses of BI an inhibitor of dipeptidyl peptidase 4,
in healthy male volunteers.  J Clin Pharmacol 1356, 48:1171-1178.
4. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F,
Mark M: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-
methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-
purine-2,6-dione (BI 1356), a novel xanthine-based dipepti-
dyl peptidase 4 inhibitor, has a superior potency and longer
duration of action compared with other dipeptidyl pepti-
dase-4 inhibitors.  J Pharmacol Exp Ther 2008, 325:175-182.
5. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W: Concentra-
tion-dependent plasma protein binding of the novel DPP-4
inhibitor BI 1356 due to saturable binding to its target in
plasma of mice, rats and humans.  J Pharm Pharmacol 2009,
61:55-62.
6. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D,
Dugi KA: Pharmacokinetics, pharmacodynamics and tolera-
bility of multiple oral doses of linagliptin, a dipeptidyl pepti-
dase-4 inhibitor in male type 2 diabetes patients.  Diabetes
Obes Metab 2009, 11:786-94.
7. Brunetti P: The lean patient with type 2 diabetes: characteris-
tics and therapy challenge.  Int J Clin Pract Suppl 2007, 153:3-9.
8. de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, Fukazawa I, van
Doorn MB, Heuvel MW van den, Machielsen CS, Uchida E, Cohen AF:
Pharmacokinetic differences between Caucasian and Japa-
nese subjects after single and multiple doses of a potential
combined oral contraceptive (Org 30659 and EE).  Contracep-
tion 2003, 68:195-202.
9. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H,
Moore R, Lee C, Chen Y, Schneck D: Rosuvastatin pharmacoki-
netics and pharmacogenetics in white and Asian subjects
residing in the same environment.  Clin Pharmacol Ther 2005,
78:330-41.
10. Pharmaceutical and Medical Devices Agency (PMDA): Points to Be
Considered by the Review Staff Involved in the Evaluation
Process of New Drug.  2008 [http://www.pmda.go.jp/english/serv
ice/pdf/points.pdf].
11. Kanada S, Watada H, Hayashi N, Sarashina A, Taniguchi A, Horie Y,
Dugi KA: Safety, Tolerability, Pharmacokinetics and Pharma-
codynamics of Multiple Doses of BI 1356 (proposed trade-
name ONDERO), a Dipeptidyl Peptidase 4 Inhibitor, in
Japanese Patients with Type 2 Diabetes [abstract].  Diabetes
2008, 57(Suppl 1):A97. (533-P)
12. Ishii H, Bradley C, Riazi A, Barendse S, Yamamoto T: The Japanese
version of the Diabetes Treatment Satisfaction Question-
naire (DTSQ) translation and clinical evaluation.  J Clin Exp
Med 2000, 192:809-814.
13. Zelen M: The randomization and stratification of patients to
clinical trials.  J Chronic Dis 1974, 27:365-75.
14. International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use: Statistical
principles for clinical trials 1998.
15. Hochberg Y, Tamhane AC: Multiple Comparison Procedures New York:
John Wiley & Sons, Inc; 1987. 
16. Kawamori R, Toyota T, Oka Y, Yamada A, Iwamoto Y, Tajima N,
Kikkawa R, Seino Y, Matsuzawa Y, Nawata H, Hotta N: Improve-
ment of glycaemic control following 12-weeks treatment
with miglitol in Japanese type 2 diabetes: a double-blind, ran-
domized, placebo- and voglibose-controlled trial [abstract].
Diabetes Metabolism 2003, 29:4s263.
17. International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use: Safety
evaluation of new drugs expected to be long-used for nonfa-
tal diseases in the clinical development.  1996, 5:32-40.
18. Molinaro RJ: Targeting HbA1c: standardization and clinical
laboratory measurement.  MLO Med Lab Obs 2008, 40:10-4. 16-9.
19. Manley S: Haemoglobin A1c--a marker for complications of
type 2 diabetes: the experience from the UK Prospective
Diabetes Study (UKPDS).  Clin Chem Lab Med 2003,
41:1182-1190.
20. Bell DS: Ethics in diabetic clinical trials.  Diabetes Care 2001,
24:606-607.